1. Home
  2. NOTV vs CELU Comparison

NOTV vs CELU Comparison

Compare NOTV & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.40

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.31

Market Cap

40.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOTV
CELU
Founded
1974
2016
Country
United States
United States
Employees
N/A
123
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7M
40.1M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
NOTV
CELU
Price
$0.40
$1.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.50
$6.00
AVG Volume (30 Days)
564.7K
80.6K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
49.64
N/A
EPS
N/A
N/A
Revenue
$547,656,000.00
N/A
Revenue This Year
$5.28
N/A
Revenue Next Year
$5.42
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
511.19
N/A
52 Week Low
$0.25
$1.01
52 Week High
$3.35
$4.35

Technical Indicators

Market Signals
Indicator
NOTV
CELU
Relative Strength Index (RSI) 53.23 51.79
Support Level $0.26 $1.21
Resistance Level $0.65 $1.33
Average True Range (ATR) 0.05 0.11
MACD 0.03 0.01
Stochastic Oscillator 70.04 61.10

Price Performance

Historical Comparison
NOTV
CELU

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: